Xenon Pharmaceuticals XENE Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's shares (diluted)?
- Xenon Pharmaceuticals (XENE) reported shares (diluted) of 87.3M in Q1 2026.
- How has Xenon Pharmaceuticals's shares (diluted) changed year-over-year?
- Xenon Pharmaceuticals's shares (diluted) increased by 11.0% year-over-year, from 78.7M to 87.3M.
- What is the long-term trend for Xenon Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's shares (diluted) has grown at a 17.7% compound annual growth rate (CAGR), from 164.8M to 316.1M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.